The Biology of Chronic Preconditioning: Genomic and Physiologic Mechanisms of Response
Primary Purpose
Ischemic Preconditioning
Status
Unknown status
Phase
Phase 2
Locations
Canada
Study Type
Interventional
Intervention
Remote ischemic preconditioning (RIPC)
Exercise
Sponsored by
About this trial
This is an interventional basic science trial for Ischemic Preconditioning focused on measuring pediatrics, Remote ischemic preconditioning
Eligibility Criteria
Inclusion Criteria:
- Age ≥ 18 years,
- Informed consent
Exclusion Criteria:
- Contraindication to exercise,
- Vigorous aerobic/anaerobic exercise in duration of ≥15 minutes during the 21 days prior to commencement of the study, or either of the RIPC or exercise protocol arms,
- Overt viral or bacterial infection in the 10 days prior to commencement of the study, or during either of the RIPC or exercise protocol arms,
- Alcohol and/or caffeine consumption in the 10 days prior to, or at any time during the study period
- Pregnancy
Sites / Locations
- The Hospital for Sick Children
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Group 1
Group 2
Arm Description
The subjects in this arm will begin on the daily remote ischemic preconditioning (RIPC) protocol for 10 days. After a 21 day washout period they will then crossover to 10 days of daily exercise.
The subjects in this arm will begin on the exercise protocol for 10 days. After a 21 day washout period they will then crossover to 10 days of daily remote ischemic preconditioning (RIPC).
Outcomes
Primary Outcome Measures
Ischemia-reperfusion injury tolerance
This will be done to assess whether chronic preconditioning in humans generates a circulating effector(s) responsible for the generation of cardioprotection in our mouse model of ischemia-reperfusion injury.
This measure will be compared over time within groups and between groups.
Ischemia-reperfusion injury tolerance
This will be done to assess whether chronic preconditioning in humans generates a circulating effector(s) responsible for the generation of cardioprotection in our mouse model of ischemia-reperfusion injury.
This measure will be compared over time within groups and between groups.
Ischemia-reperfusion injury tolerance
This will be done to assess whether chronic preconditioning in humans generates a circulating effector(s) responsible for the generation of cardioprotection in our mouse model of ischemia-reperfusion injury.
This measure will be compared over time within groups and between groups.
Ischemia-reperfusion injury tolerance
This will be done to assess whether chronic preconditioning in humans generates a circulating effector(s) responsible for the generation of cardioprotection in our mouse model of ischemia-reperfusion injury.
This measure will be compared over time within groups and between groups.
Ischemia-reperfusion injury tolerance
This will be done to assess whether chronic preconditioning in humans generates a circulating effector(s) responsible for the generation of cardioprotection in our mouse model of ischemia-reperfusion injury.
This measure will be compared over time within groups and between groups.
Ischemia-reperfusion injury tolerance
This will be done to assess whether chronic preconditioning in humans generates a circulating effector(s) responsible for the generation of cardioprotection in our mouse model of ischemia-reperfusion injury.
This measure will be compared over time within groups and between groups.
Secondary Outcome Measures
Change in skeletal muscle metabolic parameters metabolism as measured by 31P-MRS and BOLD fMRI over time within groups and between groups
Neutrophil Function - adhesion, phagocytotic index, and superoxide production over time within groups and between groups
Neutrophil Gene Expression over time within groups and between groups
Ischemia-reperfusion injury tolerance
We will assess whether chronic preconditioning in humans generates a circulating effector(s) responsible for the generation of cardioprotection in our mouse model of ischemia-reperfusion injury.
Exercise Capacity (VO2max) over time within groups and between groups
Full Information
NCT ID
NCT01164618
First Posted
July 14, 2010
Last Updated
August 14, 2013
Sponsor
The Hospital for Sick Children
1. Study Identification
Unique Protocol Identification Number
NCT01164618
Brief Title
The Biology of Chronic Preconditioning: Genomic and Physiologic Mechanisms of Response
Official Title
The Biology of Chronic Preconditioning: Genomic and Physiologic Mechanisms of Response
Study Type
Interventional
2. Study Status
Record Verification Date
August 2013
Overall Recruitment Status
Unknown status
Study Start Date
May 2010 (undefined)
Primary Completion Date
February 2013 (Actual)
Study Completion Date
January 2014 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
The Hospital for Sick Children
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to assess the effects of repeated RIPC and exercise, on exercise performance, skeletal muscle responses and circulating cellular and humoral biology in humans
Detailed Description
Remote ischemic preconditioning (RIPC) results in a powerful and widespread protective effect against subsequent prolonged ischemia-reperfusion (IR) injury of distant organs and systemic inflammatory responses, both of which are key elements in the evolution of local and multiorgan effects of many clinical IR syndromes. The signal transduction within the target organ to generate ischemia tolerance, and the effects of RIPC on systemic anti-inflammatory pathways, however, remain to be elucidated fully. Particularly, data regarding the mechanisms of 'second window' protection (a resurgence of protection 24-72 hrs after the initial RIPC stimulus) is scant; even less is known of the effects of repeated RIPC, and a potential 'third window' of protection. Our preliminary data and several recent publications have shown that the biology of RIPC and exercise show considerable overlap. This research has raised the possibility of a reciprocal effect between RIPC and exercise, with chronic exercise being a model of the potential effects of 'chronic preconditioning'. This is relevant, as repeated RIPC might be a strategy to improve exercise function in those with limited exercise tolerance e.g. heart failure.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ischemic Preconditioning
Keywords
pediatrics, Remote ischemic preconditioning
7. Study Design
Primary Purpose
Basic Science
Study Phase
Phase 2
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
12 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Group 1
Arm Type
Experimental
Arm Description
The subjects in this arm will begin on the daily remote ischemic preconditioning (RIPC) protocol for 10 days. After a 21 day washout period they will then crossover to 10 days of daily exercise.
Arm Title
Group 2
Arm Type
Experimental
Arm Description
The subjects in this arm will begin on the exercise protocol for 10 days. After a 21 day washout period they will then crossover to 10 days of daily remote ischemic preconditioning (RIPC).
Intervention Type
Procedure
Intervention Name(s)
Remote ischemic preconditioning (RIPC)
Intervention Description
RIPC will be induced using a standard blood pressure cuff and hand anaeroid sphygmomanometer, on the right arm. The subject will be seated, the blood pressure cuff placed on the arm and inflated to a pressure of 200mmHg for 5 minutes (ischemia). The cuff will then be deflated for 5 minutes (reperfusion) completing one cycle of ischemia reperfusion. A total of 4 inflation and deflation cycles will be applied. This protocol of RIPC will be applied daily, for 10 consecutive days.
Intervention Type
Other
Intervention Name(s)
Exercise
Intervention Description
Subjects will then undergo exercise daily, for 10 consecutive days. A chronic high-intensity interval exercise training protocol standardized to subjects' aerobic power (VO¬2max) will be used. Each exercise session will consist of a 5 min warm-up period followed by 4 sets of 2 min high intensity intervals interspersed with 3 min recovery periods.
Primary Outcome Measure Information:
Title
Ischemia-reperfusion injury tolerance
Description
This will be done to assess whether chronic preconditioning in humans generates a circulating effector(s) responsible for the generation of cardioprotection in our mouse model of ischemia-reperfusion injury.
This measure will be compared over time within groups and between groups.
Time Frame
Day 1 of the Excercise intervention
Title
Ischemia-reperfusion injury tolerance
Description
This will be done to assess whether chronic preconditioning in humans generates a circulating effector(s) responsible for the generation of cardioprotection in our mouse model of ischemia-reperfusion injury.
This measure will be compared over time within groups and between groups.
Time Frame
Day 1 of the RIPC intervention
Title
Ischemia-reperfusion injury tolerance
Description
This will be done to assess whether chronic preconditioning in humans generates a circulating effector(s) responsible for the generation of cardioprotection in our mouse model of ischemia-reperfusion injury.
This measure will be compared over time within groups and between groups.
Time Frame
Day 2 of the Excercise intervention
Title
Ischemia-reperfusion injury tolerance
Description
This will be done to assess whether chronic preconditioning in humans generates a circulating effector(s) responsible for the generation of cardioprotection in our mouse model of ischemia-reperfusion injury.
This measure will be compared over time within groups and between groups.
Time Frame
Day 2 of the RIPC intervention
Title
Ischemia-reperfusion injury tolerance
Description
This will be done to assess whether chronic preconditioning in humans generates a circulating effector(s) responsible for the generation of cardioprotection in our mouse model of ischemia-reperfusion injury.
This measure will be compared over time within groups and between groups.
Time Frame
Day 10 of the Excercise intervention
Title
Ischemia-reperfusion injury tolerance
Description
This will be done to assess whether chronic preconditioning in humans generates a circulating effector(s) responsible for the generation of cardioprotection in our mouse model of ischemia-reperfusion injury.
This measure will be compared over time within groups and between groups.
Time Frame
Day 10 of the RIPC intervention
Secondary Outcome Measure Information:
Title
Change in skeletal muscle metabolic parameters metabolism as measured by 31P-MRS and BOLD fMRI over time within groups and between groups
Time Frame
Days 1, 2 and 10 days of each intervention (RIPC and Excercise)
Title
Neutrophil Function - adhesion, phagocytotic index, and superoxide production over time within groups and between groups
Time Frame
Days 1, 2 and 10 of each intervention (RIPC and Excercise)
Title
Neutrophil Gene Expression over time within groups and between groups
Time Frame
Days 1, 2 and 10 of each intervention (RIPC and Excercise)
Title
Ischemia-reperfusion injury tolerance
Description
We will assess whether chronic preconditioning in humans generates a circulating effector(s) responsible for the generation of cardioprotection in our mouse model of ischemia-reperfusion injury.
Time Frame
Days 1, 2 and 10 of each intervention (RIPC and Excercise)
Title
Exercise Capacity (VO2max) over time within groups and between groups
Time Frame
Day 10 of each intervention (RIPC and Exercise)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Age ≥ 18 years,
Informed consent
Exclusion Criteria:
Contraindication to exercise,
Vigorous aerobic/anaerobic exercise in duration of ≥15 minutes during the 21 days prior to commencement of the study, or either of the RIPC or exercise protocol arms,
Overt viral or bacterial infection in the 10 days prior to commencement of the study, or during either of the RIPC or exercise protocol arms,
Alcohol and/or caffeine consumption in the 10 days prior to, or at any time during the study period
Pregnancy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andrew Redington, MD
Organizational Affiliation
The Hospital for Sick Children, Toronto Canada
Official's Role
Principal Investigator
Facility Information:
Facility Name
The Hospital for Sick Children
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G 1X8
Country
Canada
12. IPD Sharing Statement
Learn more about this trial
The Biology of Chronic Preconditioning: Genomic and Physiologic Mechanisms of Response
We'll reach out to this number within 24 hrs